Which company does Palbociclib come from?

Palbociclib (Palbociclib) is an anti-cancer drug that was developed, produced and sold by Pfizer Inc. after discovering that cyclin-dependent kinases are key regulators of cell growth.

Palbociclib is an oral inhibitor of cyclin-dependent kinase 4/6 (CDK4/6) indicated in combination with an aromatase inhibitor for the first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/her2 ABC) and in combination with fulvestrant in women with HR+/her2 ABC whose disease has progressed on prior endocrine therapy (ET). In the three randomized PALOMA clinical trials, palbociclib prolonged median progression-free survival (PFS) compared with ET alone. Furthermore, in patients with HR+/her2 ABC who were sensitive to previous ET, treatment with palbociclib plus fulvestrant improved overall survival compared with placebo plus fulvestrant.

PalbociclibThe original drug has been launched in China and has been included in medical insurance. Currently, reimbursement is only available to patients who meet the indications. The common specifications100mg*21 pills may cost more than 6,000 yuan per box, while the original drug sold overseas is more expensive. The price of 125mg*21 pills per box may be around 10,000 yuan (the price may fluctuate due to exchange rates). Palbociclib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 125mg*21 tablets produced by a Bangladesh pharmaceutical factory may be several hundred yuan (the price may fluctuate due to the exchange rate).